Sylvie Guichard
Sylvie Guichard
Director Translational Science Forma Therapeutics
Verified email at
TitleCited byYear
Guidelines for the use and interpretation of assays for monitoring autophagy
DJ Klionsky, FC Abdalla, H Abeliovich, RT Abraham, A Acevedo-Arozena, ...
Autophagy 8 (4), 445-544, 2012
AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity
CM Chresta, BR Davies, I Hickson, T Harding, S Cosulich, SE Critchlow, ...
Cancer research 70 (1), 288-298, 2010
mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling
VS Rodrik-Outmezguine, S Chandarlapaty, NC Pagano, PI Poulikakos, ...
Cancer discovery 1 (3), 248-259, 2011
Controlling ligand substitution reactions of organometallic complexes: tuning cancer cell cytotoxicity
F Wang, A Habtemariam, EPL van der Geer, R Fernández, M Melchart, ...
Proceedings of the National Academy of Sciences 102 (51), 18269-18274, 2005
Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines
S Arnould, I Hennebelle, P Canal, R Bugat, S Guichard
European journal of cancer 39 (1), 112-119, 2003
CPT-11 converting carboxylesterase and topoisomerase I activities in tumour and normal colon and liver tissues
S Guichard, C Terret, I Hennebelle, I Lochon, P Chevreau, E Fretigny, ...
British journal of cancer 80 (3-4), 364, 1999
Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): A Potent and Selective Inhibitor of ATR Protein …
KM Foote, K Blades, A Cronin, S Fillery, SS Guichard, L Hassall, I Hickson, ...
Journal of medicinal chemistry 56 (5), 2125-2138, 2013
The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia
L Willems, N Chapuis, A Puissant, TT Maciel, AS Green, N Jacque, ...
Leukemia 26 (6), 1195, 2012
Aspirin activates the NF-κB signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer
LA Stark, K Reid, OJ Sansom, FV Din, S Guichard, I Mayer, DI Jodrell, ...
Carcinogenesis 28 (5), 968-976, 2006
Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells
P Casado, JC Rodriguez-Prados, SC Cosulich, S Guichard, ...
Sci. Signal. 6 (268), rs6-rs6, 2013
Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors
EM Sommer, H Dry, D Cross, S Guichard, BR Davies, DR Alessi
Biochemical Journal 452 (3), 499-508, 2013
Practical treatment guide for dose individualisation in cancer chemotherapy
P Canal, E Chatelut, S Guichard
Drugs 56 (6), 1019-1038, 1998
Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line
S Guichard, I Hennebelle, R Bugat, P Canal
Biochemical pharmacology 55 (5), 667-676, 1998
Sequence‐dependent activity of the irinotecan‐5FU combination in human colon‐cancer model HT‐29 in vitro and in vivo
S Guichard, D Cussac, I Hennebelle, R Bugat, P Canal
International journal of cancer 73 (5), 729-734, 1997
Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells
P Sini, D James, C Chresta, S Guichard
Autophagy 6 (4), 553-554, 2010
Wild-type p53 can induce p21 and apoptosis in neuroblastoma cells but the DNA damage-induced G1 checkpoint function
PP McKenzie, SM Guichard, DS Middlemas, RA Ashmun, MK Danks, ...
Clinical cancer research 5 (12), 4199-4207, 1999
Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055)
SV Holt, A Logie, BR Davies, D Alferez, S Runswick, S Fenton, ...
Cancer research 72 (7), 1804-1813, 2012
Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation
CL Cope, R Gilley, K Balmanno, MJ Sale, KD Howarth, M Hampson, ...
J Cell Sci 127 (4), 788-800, 2014
Anti-tumour activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium (II) based organo-metallic compounds
SM Guichard, R Else, E Reid, B Zeitlin, R Aird, M Muir, M Dodds, H Fiebig, ...
Biochemical pharmacology 71 (4), 408-415, 2006
Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium (II …
RL Hayward, QC Schornagel, R Tente, JS Macpherson, RE Aird, ...
Cancer chemotherapy and pharmacology 55 (6), 577-583, 2005
The system can't perform the operation now. Try again later.
Articles 1–20